NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT06973525 2025-08-05
HER2-DM-NACT
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06832904 2025-02-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06718335 2024-12-11
Pyrotinib in HER2-positive Early Breast Cancer
Yunnan Cancer Hospital
Phase NA Not yet recruiting
NCT05635487 2024-07-05
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2 Recruiting
NCT06217185 2024-02-28
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Hebei Medical University Fourth Hospital
Phase 4 Recruiting
NCT05834764 2023-04-28
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05429294 2022-06-23
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT04481932 2020-07-22
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Peking University
Phase 2 Recruiting
NCT04158856 2019-11-12
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting